Research Studies: Parkinson's Disease

Currently Enrolling Studies

Neurodegenerative Disorders Cerebrospinal Fluid (CSF) Biorepository

• This study is investigating potential biomarkers for Parkinsonian disorders by collecting cerebrospinal fluid, the fluid that the brain sits in. Samples may also be used for future research.

• The study will collect clinical information and cerebrospinal fluid sample from individuals with any type of Parkinsonian disorder. Non-UCSD patients will first need to be seen at UCSD to confirm the diagnosis and medical history. Participation will include one study visit to complete a lumbar puncture.

Non-Invasive Continuous Ultrasonic Blood Pressure Monitoring

• This research study is evaluating the use of a continuous blood pressure monitor ultrasonic patch to learn more about orthostatic hypotension. The study is recruiting healthy volunteers and individuals with Hypotension, Prehypertension and Stage 1 or 2 hypertension.

Non-Invasive Neurophysiological Characterization of Movement Disorders

• The goal of this study is to learn more about movement disorders including tremor, Parkinson's disease, dystonia, myoclonus, neuromyotonia, ataxia, functional movement disorders, and others using non-invasive neurophysiologic techniques and clinical evaluation.
• The study also aims to teach neurologists in-training as well as other trainees in neurophysiological techniques used in the diagnosis of movement disorders.

PDGENE - Parkinson's Foundation: PDGeneration: Mapping the Future of PD

• This study is focused on assessing the impact, feasibility and participant satisfaction of offering genetic counseling as part of clinical care for people with Parkinson's Disease.

• The study will collect clinical information and cheek swab samples from individuals with Parkinson's disease at one virtual visit.
• Parkinson’s Foundation Global Genetics Study Hits Enrollment Milestone
• El estudio genético global de la Parkinson's Foundation alcanza un hito en la inscripción

A Phase 2 Study to Evaluate BIA 28-6156 in Subjects With Parkinson’s Disease With a Pathogenic Variant in the Glucocerebrosidase (GBA1) Gene

• To assess the efficacy of study drug (Bia 28-6156) in slowing disease progression and functional impairment in subjects with the GBA-PD genetic mutation
• We are looking for participants between ages of 35 and 80 with a diagnosis of Parkinson's disease.  The diagnosis of Parkinson's disease needs to be no longer than 7 years ago.

Parkinson's Progression Markers Initiative (PPMI)

• This study gathers information over time from people with and without Parkinson’s disease to learn more about how the disease starts and changes and how to stop it.

• The study is enrolling people diagnosed with Parkinson's within the past two years and not yet taking PD medication.

• Click here to view the PPMI study flier

WMMS: Development of a Wearable Multi-Modal Monitoring System (WMMS) to Determine Causes of Falls in Parkinson's Disease and Atypical Parkinsonian Disorders

• The aim of this study is to develop and test clinical applications of a wearable device that will continuously record multiple physiologic parameters such as blood pressure, heart rate, motion, and brain activity in patient's real life settings.
• This study is recruiting participants with Parkinson's disease and Atypical Parkinsonian Disorders such as Progressive Supranuclear Palsy (PSP), Corticobasal Syndrome (CBS), Corticobasal Degeneration (CBD) and Multiple System Atrophy (MSA).

Disparities in Neurocognitive Impairment Among Hispanics/Latinos in the U.S. With Parkinson's Disease: The Role of Cardiovascular Disease

• The study will investigate the disparities in neurocognition among Hispanics living in the United States (US-Mexico Borderland) with Parkinson’s disease.
• Participants must be age 40 and older, Hispanic and Non-Hispanic White, and may be either English or Spanish speaking.  
• View our information flyer in English
• Presione aquí para ver el folleto del estudio

Real-Time Microneedle Sensor Monitoring of Levodopa Levels in Parkinson's disease

• The project aims to develop a continuous, minimally invasive microneedle device called the "Levodopameter" which is designed to continuously measure levodopa levels in real time, with the future goals of identifying an individualized treatment regimen for Parkinson's disease patients to improve disease management.
• This study is recruiting participants with Parkinson's disease as well as healthy volunteers.

wAid: Web-based Automated Imaging Differentiation of Parkinson

• The study will test the performance of non-invasive biomarker to assess whether diffusion-weighted MRI can distinguish between parkinsonian syndromes using an automated imaging approach.
• This study is currently recruiting participants.

Dementia with Lewy Bodies Consortium

• The purpose of this study is to allow for the discovery of biomarkers and promote additional future research to improve the diagnosis, care and treatment in dementia with Lewy bodies.

• The consortium will collect detailed clinical information, biofluids, imaging data and ultimately autopsy results from individuals with dementia with Lewy bodies, mild cognitive impairment with a high likelihood of dementia with Lewy bodies, or Parkinson's disease dementia. There will be annual visits for up to 5 years. A study partner/caregiver is required.

• Click here to view the study flyer

 Ongoing Studies Currently Closed to Enrollment

PD0053: A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral UCB0599 in Study Participants with Early Parkinson's Disease 

• The study aims to demonstrate that UCB0599 is safe, effective and tolerable compared with placebo in patients with early Parkinson’s disease.
• Between ages of 40-75
• Recent diagnosis (less than 2 years) and has never taken medications for the treatment of Parkinson’s disease
• More information about the Orchestra study

PADOVA-BN42358: A Phase IIB, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Intravenous Parsinezumab in Participants with Early Parkinson's Disease

• The study will evaluate the efficacy, safety and pharmacokinetics of prasinezumab compared with placebo in patients with early Parkinson's Disease (PD) over the course of 76 weeks with infusions occurring every 4 weeks.
• Diagnosis of PD within 6 months to 3 years and currently being treated with either an MAO-B inhibitor or levodopa.
• Between the ages of 50-85 years old. 
• Enrollment is currently closed for this study.